Ads
related to: demyelinating polyneuropathy- Ig Without Vials
May Simplify Your
Self-Infusion Steps.
- Patient Support Programs
Review financial assistance offers,
patient stories & other resources
- Medicare Part B
Self-Infused Ig Covered Under
The Same Benefit Category As IVIg.
- Prescribing Information
Review Prescribing Information
And Patient Product Information.
- Live CIDP Events
Sign Up For Free In-Person Events
Or Webinars To Learn About CIDP
- Flexible Dosing
Infusions can be scheduled from
daily to every 2 weeks
- Ig Without Vials
Search results
Investigational Drugs for Chronic Inflammatory Demyelinating Polyneuropathy
MedPage Today· 5 days agoInvestigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy</ ...
argenx shares rise as Stifel raises price target to $485 By Investing.com
Investing.com· 4 days agoThe adjustment follows the anticipation of the Prescription Drug User Fee Act (PDUFA) date for...
Story from Argenx: “Untold Stories” Podcast Shares Powerful Tales of Strength and Perseverance Amid...
USA Today· 6 days agoIn collaboration with Ruby Studio, argenx has given voice to those who suffer from these rare...
argenx (NASDAQ:ARGX) Posts Earnings Results, Misses Expectations By $0.33 EPS
ETF DAILY NEWS· 2 days agoargenx (NASDAQ:ARGX – Get Free Report) released its earnings results on Thursday. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.33 ...
OmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 17 hours agoOmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call Transcript May 10, 2024 OmniAb, Inc. isn’t one of...
Hawaii Specialty Pharmacy Announces New Ambulatory Infusion Centers to Serve Maui Community, Invites...
FOX 59 Indianapolis· 5 days agoHawaii Specialty Pharmacy (HSP), a leading provider of specialty infusion pharmacy services with a...
Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024
VentureBeat· 7 days agoPress Release Komodo Health today announced the publication of 33 new health economics and outcomes...
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) PT at $48.00
ETF DAILY NEWS· 2 days agoShares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average rating of “Buy” from the seventeen ratings firms that are covering the company, Marketbeat.com reports. Seventeen ...
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by New York State Common Retirement Fund
ETF DAILY NEWS· 3 days agoNew York State Common Retirement Fund grew its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 30.2% in the 4th quarter, according to its most recent Form 13F filing with ...
Q1 2024 Halozyme Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoThe new indication is for maintenance treatment of patients with chronic inflammatory demyelinating polyneuropathy ...
